Zimmermannova, Olga
Ferreira, Alexandra Gabriela
Pereira, Carlos-Filipe http://orcid.org/0000-0002-9724-1382
Article History
Received: 31 October 2023
Revised: 28 November 2023
Accepted: 1 December 2023
First Online: 15 December 2023
Competing interests
: C-FP has equity interest and serves in management positions at Asgard Therapeutics AB, which develops cancer immunotherapies based on DC reprogramming technologies. The other authors declare no competing interests.